indazoles has been researched along with Diarrhea in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 22 (81.48) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Connell, W; MacIsaac, M; Wu, K | 1 |
| Brown, JN; Hammond, JM; Lee, S; Sneed, GT | 1 |
| Cao, X; Gao, W; Jin, L; Poole, A; Ratto, B; Ravichandran, S; Swallow, E; Tang, D; Vogelzang, NJ | 1 |
| Bertucci, F; Blay, JY; Bompas, E; Brodowicz, T; Chaigneau, L; Chevreau, C; Decoupigny, E; Delcambre, C; Italiano, A; Laroche, L; Le Cesne, A; Le Deley, MC; Mir, O; Penel, N; Ray-Coquard, I; Saada-Bouzid, E; Salas, S; Taieb, S; Vanseymortier, M; Wallet, J | 1 |
| de Geeter, P; Goebell, PJ; Grünwald, V; Herrmann, E; Hogrefe, C; Marschner, N; Merling, M; Panic, A; Potthoff, K; Staehler, M; Vannier, C | 1 |
| Dinkic, C; Eichbaum, M; Fricke, HC; Gebauer, G; Grischke, EM; Lenz, F; Marme, F; Rom, J; Schmidt, M; Schneeweiss, A; Sohn, C; Wallwiener, M | 1 |
| Gunderson, CC; Matulonis, U; Moore, KN | 1 |
| Adjei, AA; Bishop, WR; Carr, D; Chun, P; Cooper, A; Dayananth, P; Deng, Y; Flaherty, KT; Fong, PC; Hwu, WJ; Kirschmeier, P; Long, BJ; Miselis, NR; Moreno, BH; Moschos, SJ; Ramanathan, RK; Ribas, A; Robert, L; Rubin, EH; Rubino, J; Rush, TS; Samatar, AA; Schiller, J; Shapira-Frommer, R; Shipps, GW; Sullivan, RJ; Tawbi, HA; Zhang, D | 1 |
| Cresta, S; Damian, S; Gendreau, S; Mayer, IA; Morrissey, KM; Ng, VW; Rooney, I; Schöffski, P; Singel, SM; Spoerke, JM; Wildiers, H; Winer, E | 1 |
| Beerahee, M; Cahn, A; Graves, R; Hall, D; Hodgson, S; Hughes, SC; Robertson, J; Solari, R; van Marle, S; Watson, J; Wilson, R; Young, G | 1 |
| Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H | 1 |
| Bodoky, G; Bodrogi, I; Csejtei, A; Dank, M; Géczi, L; Küronya, Z; Mangel, L; Maráz, A; Petrányi, A; Szûcs, M | 1 |
| Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M | 1 |
| Agate, L; Boucher, A; Bycott, P; Chen, C; Cohen, EE; Ingrosso, A; Jarzab, B; Kane, MA; Kim, S; Licitra, L; Locati, LD; Ou, SH; Pithavala, YK; Qin, S; Wirth, LJ | 1 |
| Davis, ID; Deen, KC; Hawkins, RE; Sigal, E; Sternberg, CN | 1 |
| Bauer, TM; Bendell, JC; Burris, HA; Hinson, JM; Infante, JR; Jones, S; Orlemans, EO; Ramanathan, RK; Tibes, R; Von Hoff, DD; Weiss, GJ | 1 |
| Greenberg, A; Matta, SK; Singh, A | 1 |
| Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
| Dowlati, A; Gibson, DM; Hodge, JP; Hurwitz, HI; Merkle, EM; Pandite, L; Saini, S; Savage, S; Suttle, AB | 1 |
| Altorki, N; Bauer, T; Felip, E; Grannis, FW; Guarino, MJ; Gurpide, A; Huff, A; Lane, ME; Lee, PC; Mitchell, JD; Ottesen, LH; Pass, H; Peylan-Ramu, N; Reeves, A; Roychowdhury, DF; Swann, RS; Tachdjian, S; Yankelevitz, DF | 1 |
| Chowbay, B; Gao, F; Goh, BC; Ivy, P; Koh, TS; Leong, SS; Lim, WT; Ng, QS; Singh, O; Tan, DS; Tan, EH; Thng, CH; Toh, CK | 1 |
| Chatta, G; Hussain, M; Karrison, T; O'Donnell, PH; Posadas, EM; Shevrin, D; Stadler, WM; Szmulewitz, RZ; Ward, JE | 1 |
| Chen, Y; Garrett, M; Hee, B; Klamerus, KJ; LaBadie, RR; Mount, J; Ni, G; Pithavala, YK; Selaru, P; Toh, M; Tortorici, MA | 1 |
| Ansell, P; Carlson, DM; Carr, BI; Chen, PJ; Dowell, B; Gill, S; Knox, JJ; McKeegan, EM; Pedersen, M; Qian, J; Qin, Q; Ricker, JL; Scappaticci, FA; Toh, HC; Yong, WP | 1 |
| Alvarez, RH; Blackwell, KL; Cristofanilli, M; Gladkov, O; Gomez, HL; Johnston, SR; Manikhas, A; Ranganathan, S; Redhu, S; Rubin, SD; Safina, S; Shao, Z; Trudeau, ME | 1 |
| Barrios, CH; Chen, M; Davis, ID; Gladkov, OA; Hawkins, RE; Lee, E; Mardiak, J; McCann, L; Rubin, SD; Salman, P; Sternberg, CN; Szczylik, C; Wagstaff, J; Zarba, JJ | 1 |
| Andrews, L; Fishman, M; Gorbunova, V; Jonasch, E; Larkin, J; Negrier, S; Olivier, K; Pyle, L; Staehler, M; Wood, L | 1 |
4 review(s) available for indazoles and Diarrhea
| Article | Year |
|---|---|
Gastrointestinal: Diarrhea in a patient treated with pazopanib: A rare case of a common adverse effect.
Topics: Angiogenesis Inhibitors; Diarrhea; Gastrointestinal Tract; Humans; Indazoles; Kidney Neoplasms; Pyrimidines | 2023 |
The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Fatigue; Humans; Hypertension; Indazoles; Kidney Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2019 |
Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Autoimmune Diseases; Bevacizumab; Diarrhea; Epistaxis; Fatigue; Female; Genital Neoplasms, Female; Headache; Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Perforation; Molecular Targeted Therapy; Nausea; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Proteinuria; Pyrimidines; Risk Assessment; Sulfonamides; Vomiting; Water-Electrolyte Imbalance | 2018 |
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting | 2014 |
18 trial(s) available for indazoles and Diarrhea
| Article | Year |
|---|---|
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Cross-Over Studies; Diarrhea; Disease Progression; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome | 2020 |
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Hypothyroidism; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2021 |
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Indazoles; Leukopenia; Liver Function Tests; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Pyrimidines; Sulfonamides | 2017 |
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Cell Line, Tumor; Diarrhea; Dogs; Dose-Response Relationship, Drug; Drug Eruptions; Drug Evaluation, Preclinical; Fatigue; Female; Humans; Indazoles; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nausea; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Rats; Triazoles; Xenograft Model Antitumor Assays; Young Adult | 2018 |
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cohort Studies; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Letrozole; Middle Aged; Nausea; Paclitaxel; Sulfonamides; Trastuzumab | 2018 |
Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study.
Topics: Abdominal Pain; Administration, Oral; Adult; Aged; Area Under Curve; Biological Availability; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Headache; Humans; Indazoles; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Receptors, CCR4; Rhinitis; Sulfonamides; Young Adult | 2013 |
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proteinuria; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Thyroid Neoplasms; Treatment Outcome | 2014 |
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anorexia; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hair Color; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Pyrimidines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2014 |
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Benzamides; Biological Availability; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glycine; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs; Vision Disorders | 2014 |
Phase I trial of pazopanib in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Anorexia; Cohort Studies; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Pyrimidines; Sulfonamides; Vomiting | 2009 |
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Fatigue; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypertension; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Sulfonamides; Treatment Outcome | 2010 |
A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anorexia; Asian People; Carcinoma; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrimidines; Sulfonamides; Treatment Outcome; Vomiting | 2011 |
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.
Topics: Antineoplastic Agents; Chicago; Diarrhea; Early Termination of Clinical Trials; Fatigue; Humans; Indazoles; Male; Orchiectomy; Patient Compliance; Prostatic Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome; United States; United States Department of Defense; Universities | 2012 |
Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
Topics: Adult; Aged; Axitinib; Cross-Over Studies; Diarrhea; Dietary Fats; Energy Intake; Fasting; Fatigue; Female; Food-Drug Interactions; Humans; Imidazoles; Indazoles; Male; Middle Aged; Nausea; Tablets; Young Adult | 2012 |
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Phenylurea Compounds; Treatment Outcome; Tumor Burden; Young Adult | 2013 |
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Female; Humans; Indazoles; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cross-Over Studies; Diarrhea; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome | 2013 |
5 other study(ies) available for indazoles and Diarrhea
| Article | Year |
|---|---|
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sulfonamides; Time Factors | 2020 |
[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Humans; Hungary; Hypertension; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Treatment Outcome | 2013 |
Diarrhea With Clostridium difficile-Positive Stool-Trick or Treat: A Teachable Moment.
Topics: Aged; Anti-Bacterial Agents; Axitinib; Carcinoma, Renal Cell; Clostridioides difficile; Costs and Cost Analysis; Diagnosis, Differential; Diarrhea; Enterocolitis, Pseudomembranous; Feces; Female; Humans; Imidazoles; Indazoles; Metronidazole; Protein Kinase Inhibitors; Recurrence; Treatment Outcome; Vancomycin; Withholding Treatment | 2015 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.
Topics: Axitinib; Carcinoma, Renal Cell; Diarrhea; Dysphonia; Fatigue; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Nausea; Protein Kinase Inhibitors; Proteinuria; Vomiting | 2014 |